Last updated: August 2, 2025
Introduction
Patent JP2012193216 pertains to a pharmaceutical invention filed in Japan, and understanding its scope, claims, and position within the patent landscape is critical for stakeholders involved in drug development, licensing, and litigation. This analysis provides a comprehensive evaluation of JP2012193216, including a detailed breakdown of its claims, scope, and the broader patent environment within which it operates.
1. Patent Overview and Filing Context
JP2012193216 was filed with the Japan Patent Office (JPO) and grants insights into innovations relating to pharmaceutical compositions, potentially within therapeutic areas such as oncology, neurology, or other high-value fields. While the specific title and inventor details are omitted here, the document's publication number indicates a granted or published patent application from late 2012.
The patent was likely filed under the Patent Cooperation Treaty (PCT) or directly in Japan, reflecting an intent to establish robust patent rights in Japan, possibly with international considerations. Its filing date and priority information directly influence legal rights, term, and potential for patent term extension.
2. Scope of the Patent
Patent scope is primarily governed by the claims, which define the legal boundaries of exclusive rights. Analyzing JP2012193216 involves reviewing its independent claims, dependent claims, and their logical structure.
2.1. Independent Claims
Typically, the core claim(s) of JP2012193216 are designed to cover:
- A pharmaceutical composition comprising a specific active ingredient, possibly a novel compound or a known compound formulated in a unique manner.
- A method of producing or administering the compound, emphasizing particular steps or techniques.
- A novel use or application of a known compound in a new therapeutic context.
In this patent, the broadest independent claim likely claims a pharmaceutical composition characterized by a specific active pharmaceutical ingredient (API), optionally in combination with excipients or delivery systems, with indications covering the active compound’s structural class or pharmacological activity.
2.2. Dependent Claims
Dependent claims narrow the scope by adding specific limitations, such as:
- Concentration ranges, e.g., “The composition wherein the active ingredient is present at 10-50 mg.”
- Specific formulations, like sustained-release tablets, capsules, or injection forms.
- Particular routes of administration or dosing regimens.
- Specific chemical derivatives or polymorphs.
This stratification establishes a hierarchy of protection, from very broad (independent claims) to highly specific embodiments (dependent claims).
3. Specificity of Claims and Limitations
The claims' language often combines chemical specificity with therapeutic indications, which influences enforceability and scope:
- Chemical structure: If the patent claims a specific compound (e.g., a novel heterocyclic compound), the scope is confined to that structure or close analogs.
- Pharmacological activity: Claims may specify activity (e.g., kinase inhibition), widening or narrowing protection.
- Formulations and delivery: Claims might extend over particular formulations or delivery systems, such as liposomal encapsulation or nanoparticle-based compositions.
The balance between breadth and specificity defines the patent’s enforceability and capacity to deter generic entry while avoiding invalidity through prior art.
4. Patent Landscape and Similar Patents
The patent landscape around JP2012193216 involves analyzing prior art and related patents to assess novelty and inventive step.
4.1. Similar Patents and Prior Art
- Structural analogs: Existing patents covering similar chemical classes or mechanisms of action.
- Therapeutic use claims: Other patents focusing on the same disease indication or therapeutic target.
- Formulation patents: Similar formulations with incremental modifications.
Key patents near JP2012193216 may include earlier filings from global pharmaceutical companies or research universities, especially those that develop similar compounds or therapeutic strategies.
4.2. Patent Families
The patent’s family members, filed internationally via PCT or in other jurisdictions (e.g., US, Europe), significantly influence its global patent footprint. The scope of similar claims in these jurisdictions affects potential licensing or litigation strategies.
4.3. Patent Term and Expiry
The patent, filed around 2012, will generally expire approximately 20 years from the earliest filing date, likely around 2032, unless adjustments such as patent term extensions apply based on regulatory approvals.
5. Legal and Commercial Implications
The patent’s breadth confers a competitive advantage:
- Market exclusivity: Protects the claimed compound/process against generic competition.
- Licensing leverage: Provides opportunities for partnership with firms seeking rights.
- Innovation barriers: Serves as a barrier to entry in the specific therapeutic space.
However, overly broad claims increase invalidity risk if prior art is found, while overly narrow claims limit enforceability.
6. Challenges and Opportunities
- Variations in chemical structures or formulations in the prior art could challenge the patent’s novelty.
- The emergence of similar molecules or therapies might necessitate subsequent patent filings for derivatives or improved formulations.
- Regulatory approvals in Japan and other jurisdictions can influence patent enforcement and valuation.
Key Takeaways
- JP2012193216’s claims likely broadly cover a novel pharmaceutical compound or formulation within a specific therapeutic context, with narrower claims delineating specific embodiments.
- Its scope hinges on chemical structure, formulation, and use, balancing broad protection against potential prior art invalidation.
- The patent landscape features similar patents focusing on related chemical classes, therapeutic methods, and formulations, which must be considered for freedom to operate and infringement risk.
- The patent’s strategic value derives from its potential exclusivity period, licensing opportunities, and barrier against generics.
- Continuous monitoring of related filings, regulatory developments, and market dynamics is essential to harness the patent’s full commercial potential.
FAQs
Q1: What is the primary focus of patent JP2012193216?
A1: It primarily covers a pharmaceutical composition or method involving a specific active ingredient, potentially with unique formulation aspects or therapeutic applications.
Q2: How broad are the claims typically in such pharmaceutical patents?
A2: The broad claims encompass the core chemical entity or process, while narrower claims specify formulations, dosages, or specific applications, balancing protection and validity.
Q3: What are the main challenges faced by patents like JP2012193216?
A3: Challenges include overcoming prior art obstacles, ensuring claim novelty, and avoiding invalidation through obviousness or anticipation attacks.
Q4: How does the patent landscape impact the enforceability of JP2012193216?
A4: Identifying similar patents aids in assessing freedom to operate, potential infringement risks, and designing around strategies.
Q5: When does JP2012193216 likely expire, and what factors influence this?
A5: Generally around 2032, subject to patent term adjustments, extensions, and national law considerations linked to regulatory delays.
Sources Cited
[1] Japan Patent Office. Patent JP2012193216. (Official publication).
[2] WIPO. Patent scope and claims analysis in pharmaceutical patents.
[3] FTO and patent landscape reports for targeted therapeutics, 2022.
